Coya Therapeutics (NASDAQ:COYA) focuses on developing innovative therapies aimed at combating a wide range of autoimmune, neurodegenerative, and aging-related diseases. By harnessing the power of regulatory T cells (Tregs) and leveraging advanced biotechnological processes, Coya Therapeutics aims to pave new pathways in the treatment of conditions like ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, and systemic lupus erythematosus (SLE). Central to their mission is the commitment to advancing clinical research, with several key projects in various stages of development aimed at unlocking the therapeutic potential of Tregs. Their objectives include not only advancing the science behind autoimmune and neurodegenerative disease treatments but also improving the quality of life for patients suffering from these challenging conditions.